FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204161485> ?p ?o ?g. }

• W3204161485 abstract "LEMVIDA es un estudio de práctica clínica, prospectivo, de tres años de seguimiento sobre calidad de vida en pacientes con esclerosis múltiple (EM) tratados con alemtuzumab en España. Análisis intermedio de las características basales de los pacientes que iniciaron alemtuzumab entre octubre de 2016 y septiembre de 2018. Se realizaron tres subanálisis en función de: puntuación EDSS basal; periodo de inicio de alemtuzumab durante el reclutamiento (cohorte 1: octubre de 2016 a marzo de 2017, cohorte 2: abril a septiembre de 2017; cohorte 3: octubre de 2017 a marzo de 2018, y cohorte 4: abril a septiembre de 2018); y criterios de EM muy activa. Se analizaron a 161 pacientes: 67,1% mujeres, edad 38,7 ± 9,4 años, duración EM 8,5 ± 6,0 años, EDSS 3,3 ± 1,7 y número de brotes en los dos años previos 1,8 ± 1,3. El 48,3% presentaba lesiones realzadas con gadolinio (Gd +) (media: 5,2 ± 6,9) y el 63,1% había recibido tratamiento previo con fingolimod o natalizumab. En el momento basal, la puntuación EDSS y el número de lesiones Gd + fue significativamente superior en la cohorte 1 que en la cohorte 4 (4,1 ± 1,8 vs. 3,2 ± 1,7; p = 0,040 y 10,9 ± 11,9 vs. 4,5 ± 5,7; p = 0,020). La frecuencia de tratamiento previo con fingolimod y natalizumab fue menor en la cohorte 4 (60,6%) que en la cohorte 1 (70,6%) (comparación entre grupos no analizada). A diferencia de los estudios fase 3 de alemtuzumab, los pacientes incluidos en LEMVIDA tienen mayor edad, duración de la EM y discapacidad, y han recibido inmunosupresores previos. Sin embargo, a lo largo del reclutamiento se tiende a adelantar el inicio de alemtuzumab, probablemente debido a la evidencia de una mayor efectividad en etapas tempranas. LEMVIDA is a real-world prospective study of 3-year follow-up on quality of life of patients with multiple sclerosis (MS) receiving alemtuzumab in Spain. This is an interim analysis evaluating the baseline characteristics of patients who started alemtuzumab between October 2016-September 2018. For 3 additional subanalysis patients were categorized by baseline EDSS score; time of alemtuzumab initiation during the recruitment period (cohort 1: October 2016-March 2017, cohort 2: April-September 2017, cohort 3: October 2017-March 2018 and cohort 4: April-September 2018); and the presence of highly active MS criteria. 161 patients were analyzed: 67.1% female, age 38.7 ± 9.4 years, MS duration 8.5 ± 6.0 years, EDSS 3.3 ± 1.7 and number of relapses in the previous 2 years 1.8 ± 1.3. 48.3% of patients presented gadolinium-enhanced (Gd +) lesions (mean: 5.2 ± 6.9) and 63.1% had received prior treatment with fingolimod or natalizumab. Baseline EDSS scores and number of Gd + lesions were higher in cohort 1 than in cohort 4 (4.1 ± 1.8 vs. 3.2 ± 1.7; p = 0.040 and 10.9 ± 11.9 vs 4.5 ± 5.7; p = 0.020). The frequency of prior treatment with fingolimod and natalizumab was lower in cohort 4 (60.6%) than in cohort 1 (70.6%) (comparison between groups not analyzed). Unlike phase 3 studies of alemtuzumab, the patients included in LEMVIDA are older, have a longer duration of MS, higher disability and have received previous immunosuppressants. However, throughout the recruitment period, there is a tendency towards an early beginning of treatment with alemtuzumab, probably due to the evidence of higher effectiveness in the early stages of MS." @default.
• W3204161485 created "2021-10-11" @default.
• W3204161485 creator A5011430424 @default.
• W3204161485 creator A5022338962 @default.
• W3204161485 creator A5033103609 @default.
• W3204161485 creator A5038315518 @default.
• W3204161485 creator A5040203488 @default.
• W3204161485 creator A5076965449 @default.
• W3204161485 creator A5077701566 @default.
• W3204161485 creator A5084533779 @default.
• W3204161485 date "2021-10-01" @default.
• W3204161485 modified "2023-10-01" @default.
• W3204161485 title "Inicio temprano de alemtuzumab: cambio en el paradigma de tratamiento en esclerosis múltiple. Análisis intermedio del estudio LEMVIDA" @default.
• W3204161485 cites W1580539462 @default.
• W3204161485 cites W1666336517 @default.
• W3204161485 cites W1968558564 @default.
• W3204161485 cites W1981873608 @default.
• W3204161485 cites W2015285729 @default.
• W3204161485 cites W2042166711 @default.
• W3204161485 cites W2099192606 @default.
• W3204161485 cites W2107422246 @default.
• W3204161485 cites W2127001605 @default.
• W3204161485 cites W2134033939 @default.
• W3204161485 cites W2148766438 @default.
• W3204161485 cites W2158202057 @default.
• W3204161485 cites W2552609792 @default.
• W3204161485 cites W2626225244 @default.
• W3204161485 cites W2746924405 @default.
• W3204161485 doi "https://doi.org/10.1016/j.nrl.2021.06.007" @default.
• W3204161485 hasPublicationYear "2021" @default.
• W3204161485 type Work @default.
• W3204161485 sameAs 3204161485 @default.
• W3204161485 citedByCount "1" @default.
• W3204161485 countsByYear W32041614852023 @default.
• W3204161485 crossrefType "journal-article" @default.
• W3204161485 hasAuthorship W3204161485A5011430424 @default.
• W3204161485 hasAuthorship W3204161485A5022338962 @default.
• W3204161485 hasAuthorship W3204161485A5033103609 @default.
• W3204161485 hasAuthorship W3204161485A5038315518 @default.
• W3204161485 hasAuthorship W3204161485A5040203488 @default.
• W3204161485 hasAuthorship W3204161485A5076965449 @default.
• W3204161485 hasAuthorship W3204161485A5077701566 @default.
• W3204161485 hasAuthorship W3204161485A5084533779 @default.
• W3204161485 hasBestOaLocation W32041614851 @default.
• W3204161485 hasConcept C118552586 @default.
• W3204161485 hasConcept C142362112 @default.
• W3204161485 hasConcept C15708023 @default.
• W3204161485 hasConcept C2780640218 @default.
• W3204161485 hasConcept C2781004633 @default.
• W3204161485 hasConcept C29456083 @default.
• W3204161485 hasConcept C71924100 @default.
• W3204161485 hasConceptScore W3204161485C118552586 @default.
• W3204161485 hasConceptScore W3204161485C142362112 @default.
• W3204161485 hasConceptScore W3204161485C15708023 @default.
• W3204161485 hasConceptScore W3204161485C2780640218 @default.
• W3204161485 hasConceptScore W3204161485C2781004633 @default.
• W3204161485 hasConceptScore W3204161485C29456083 @default.
• W3204161485 hasConceptScore W3204161485C71924100 @default.
• W3204161485 hasLocation W32041614851 @default.
• W3204161485 hasOpenAccess W3204161485 @default.
• W3204161485 hasPrimaryLocation W32041614851 @default.
• W3204161485 hasRelatedWork W1127731738 @default.
• W3204161485 hasRelatedWork W1995515455 @default.
• W3204161485 hasRelatedWork W1999344589 @default.
• W3204161485 hasRelatedWork W2024253875 @default.
• W3204161485 hasRelatedWork W2080531066 @default.
• W3204161485 hasRelatedWork W2164917464 @default.
• W3204161485 hasRelatedWork W2748952813 @default.
• W3204161485 hasRelatedWork W2789448498 @default.
• W3204161485 hasRelatedWork W2899084033 @default.
• W3204161485 hasRelatedWork W3032375762 @default.
• W3204161485 isParatext "false" @default.
• W3204161485 isRetracted "false" @default.
• W3204161485 magId "3204161485" @default.
• W3204161485 workType "article" @default.